The role of multimodality therapy (MMT) in unresectable hilar cholangiocarcinoma (UHC).

• DOI: 10.1200/jco.2011.29.15_suppl.e14626
• Publication Date: 2017-02-23T18:58:03Z
• Authors: N. A. Bhadkamkar; S. P. Kar; J. Weatherly; C. R. Garrett; J. Vauthey; A. O. Kaseb; P. Das; M. M. Javle
• Keywords: Biliary stent

e14626 Background: Unresectable hilar cholangiocarcinoma is commonly treated with gemcitabine-based chemotherapy. Consolidative radiotherapy (RT) increasingly being used for patients localized disease. Biliary obstruction and cholangitis are important causes of morbidity mortality in UHC. The impact MMT vs. chemotherapy alone on survival biliary has not yet been characterized. Methods: Using the MD Anderson tumor registry, we identified 137 UHC from 1998-2009 retrospectively reviewed their records demographic, epidemiologic, treatment data. We performed analyses overall (OS) using Kaplan-Meier method stratification by extent disease (locally advanced metastatic). Pearson chi-square test to analyze RT measures disease-related morbidity. Results: median OS entire group was 48 weeks. 64% had locally 71% received at least one line therapy. Patients receiving first-line gemcitabine plus cisplatin (n=42) a superior when compared those other therapies (n=55; 71 weeks 50 weeks, p=0.02). There no significant improvement who (n=48) never (n=49; 58 54 p=0.96). However, consolidative (n=13) 113 70 (n=29) [p=0.11]. did significantly reduce UHC, including non-elective stent exchanges (p=0.79), admissions obstructive jaundice or (p=0.57), non-elective, cancer-related (p=0.69). Conclusions: This series confirms previously reported setting bile duct tumors. role reducing complications remains unclear. may increase selected alone, although this requires further investigation prospective, randomized clinical trials.